The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Xiang, Yu Zhu ^a   Xiong, Hui ^a   Cui, Zi Lian ^a   Jiang, Shao Bo ^a   Xia, Qing Hua ^a   Zhao, Yong ^a   Li, Guan Bin ^a   Jin, Xun Bo ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Aggressiveness; Clinical stage; Gleason score; Recurrence

Indexed keywords

ADVANCED CANCER; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; EMBASE; GLEASON SCORE; HUMAN; LONGITUDINAL STUDY; MEDLINE; META ANALYSIS; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSTATE CANCER; SYSTEMATIC REVIEW;

COHORT STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; METABOLIC SYNDROME X; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84874826132     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-9     Document Type: Article

References (45)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 2 69 90 10.3322/caac.20107 21296855
2. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. Siegel R, Ward E, Brawley O, Jemal A, CA Cancer J Clin 2011 61 4 212 236 10.3322/caac.20121 21685461
3. Prostate cancer. Nelson WG, De Marzo AM, Isaacs WB, N Engl J Med 2003 349 4 366 381 10.1056/NEJMra021562 12878745 (Pubitemid 36886244)
4. Banting lecture 1988. Role of insulin resistance in human disease. Reaven GM, Diabetes 1988 37 12 1595 1607 10.2337/diabetes.37.12.1595 3056758 (Pubitemid 19004941)
5. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr, Circulation 2009 120 16 1640 1645 10.1161/CIRCULATIONAHA.109.192644 19805654
6. Metabolic syndrome and cancer. Pothiwala P, Jain SK, Yaturu S, Metab Syndr Relat Disord 2009 7 4 279 288 10.1089/met.2008.0065 19284314
7. Metabolic syndrome and endometrial cancer risk. Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, Negri E, Franceschi S, La Vecchia C, Ann Oncol 2011 22 4 884 889 10.1093/annonc/mdq464 20937645
8. Metabolic syndrome is associated with colorectal cancer in men. Pelucchi C, Negri E, Talamini R, Levi F, Giacosa A, Crispo A, Bidoli E, Montella M, Franceschi S, La Vecchia C, Eur J Cancer 2010 46 10 1866 1872 10.1016/j.ejca.2010.03.010 20395126
9. Metabolic syndrome and pancreatic cancer risk: a case-control study in Italy and meta-analysis. Rosato V, Tavani A, Bosetti C, Pelucchi C, Talamini R, Polesel J, Serraino D, Negri E, La Vecchia C, Metabolism 2011 60 10 1372 1378 10.1016/j.metabol.2011.03.005 21550085
10. Symposium introduction: metabolic syndrome and the onset of cancer. Zhou JR, Blackburn GL, Walker WA, Am J Clin Nutr 2007 86 3 817 s819 18265474
11. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT, Cancer Epidemiol Biomarkers Prev 2004 13 10 1646 1650 15466982 (Pubitemid 39331887)
12. The metabolic syndrome is associated with reduced risk of prostate cancer. Tande AJ, Platz EA, Folsom AR, Am J Epidemiol 2006 164 11 1094 1102 10.1093/aje/kwj320 16968859 (Pubitemid 44851745)
13. Metabolic syndrome and cancer risk. Russo A, Autelitano M, Bisanti L, Eur J Cancer 2008 44 2 293 297 10.1016/j.ejca.2007.11.005 18055193
14. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI, Cancer Causes Control 2009 20 7 1181 1192 10.1007/s10552-009-9319-x 19277881
15. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Inoue M, Noda M, Kurahashi N, Iwasaki M, Sasazuki S, Iso H, Tsugane S, Eur J Cancer Prev 2009 18 3 240 247 10.1097/CEJ.0b013e3283240460 19491612
16. The metabolic syndrome and the risk of prostate cancer under competing risks of death from other causes. Grundmark B, Garmo H, Loda M, Busch C, Holmberg L, Zethelius B, Cancer Epidemiol Biomarkers Prev 2010 19 8 2088 2096 10.1158/1055-9965.EPI-10-0112 20647401
17. The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: Results from the Olmsted County Study. Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV, BJU Int 2011 107 6 929 935 10.1111/j.1464-410X.2010.09703.x 20880183
18. Metabolic syndrome and incidence of liver and breast cancers in Japan. Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T, Cancer Epidemiol 2012 36 2 141 147 10.1016/j.canep.2011.03.007 21890443
19. Prospective study on metabolic factors and risk of prostate cancer. Haggstrom C, Stocks T, Ulmert D, Bjorge T, Ulmer H, Hallmans G, Manjer J, Engeland A, Nagel G, Almqvist M, et al. Cancer 2012 118 24 6199 6206 10.1002/cncr.27677 23090855
20. Racial differences in risk of prostate cancer associated with metabolic syndrome. Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, Rundle A, Bock CH, Tang D, Jankowski M, Rybicki BA, Urology 2009 74 1 185 190 10.1016/j.urology.2009.03.013 19428088
21. The metabolic syndrome and risk of prostate cancer in Italy. Pelucchi C, Serraino D, Negri E, Montella M, Dellanoce C, Talamini R, La Vecchia C, Ann Epidemiol 2011 21 11 835 841 10.1016/j.annepidem.2011.07.007 21982487
22. Metabolic Syndrome and Risk of Cancer: A systematic review and meta-analysis. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D, Diabetes Care 2012 35 11 2402 2411 10.2337/dc12-0336 23093685
23. Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. Castillejos-Molina R, Rodriguez-Covarrubias F, Sotomayor M, Gomez-Alvarado MO, Villalobos-Gollas M, Gabilondo F, Feria-Bernal G, Urol Int 2011 87 3 270 275 10.1159/000329280 21876327
24. Effect of metabolic syndrome on pathologic features of prostate cancer. Kheterpal E, Sammon JD, Diaz M, Bhandari A, Trinh QD, Pokala N, Sharma P, Menon M, Agarwal PK, Urol Oncol 2012 Epub ahead of print
25. Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy. De Nunzio C, Freedland SJ, Miano R, Trucchi A, Cantiani A, Carluccini A, Tubaro A, Prostate 2011 Epub ahead of print
26. Metabolic syndrome increases the risk of aggressive prostate cancer detection. Morote J, Ropero J, Planas J, Bastaros JM, Delgado G, Placer J, Celma A, de Torres IM, Carles J, Reventos J, et al. BJU Int 2012 Epub ahead of print
27. The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy. Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, Rundle A, Jankowski M, Rybicki BA, Prostate Cancer 2011 2011 245642 22096652
28. Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy. Jeon KP, Jeong TY, Lee SY, Hwang SW, Shin JH, Kim DS, Korean J Urol 2012 53 9 593 597 10.4111/kju.2012.53. 9.593 23060995
29. The characteristics of prostate cancer with metabolic syndrome in Korean men. B.K H, Korean J Urol 2007 48 6 585 591 10.4111/kju.2007.48.6.585
30. Metabolic syndrome and risk of cancer mortality in men. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN, Eur J Cancer 2009 45 10 1831 1838 10.1016/j.ejca.2009.01.031 19250819
31. Patients with metabolic syndrome and widespread high grade prostatic intraepithelial neoplasia are at a higher risk factor of prostate cancer on re-biopsy: a prospective single cohort study. Antonio C, Francesco C, Cosimo DN, Andrea T, Rocco D, Urol Oncol 2012 Epub ahead of print
32. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Hammarsten J, Hogstedt B, Eur J Cancer 2005 41 18 2887 2895 10.1016/j.ejca.2005.09.003 16243513 (Pubitemid 41713128)
33. Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. Asmar R, Beebe-Dimmer JL, Korgavkar K, Keele GR, Cooney KA, Prostate Cancer Prostatic Dis 2012 Epub ahead of print
34. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Lund Haheim L, Wisloff TF, Holme I, Nafstad P, Am J Epidemiol 2006 164 8 769 774 10.1093/aje/kwj284 16952929 (Pubitemid 44522081)
35. Features of the metabolic syndrome and prostate cancer in African-American men. Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA, Cancer 2007 109 5 875 881 10.1002/cncr.22461 17265528 (Pubitemid 46333529)
36. Quantifying heterogeneity in a meta-analysis. Higgins JP, Thompson SG, Stat Med 2002 21 11 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
37. Obesity, metabolic syndrome, and prostate cancer. Hsing AW, Sakoda LC, Chua S Jr, Am J Clin Nutr 2007 86 3 843 857 18265478
38. Diabetes mellitus and risk of prostate cancer: an updated meta-analysis based on 12 case-control and 25 cohort studies. Zhang F, Yang Y, Skrip L, Hu D, Wang Y, Wong C, Qiu J, Lei H, Acta Diabetol 2012 Epub ahead of print
39. The role of JAZF1 on lipid metabolism and related genes in vitro. Li L, Yang Y, Yang G, Lu C, Yang M, Liu H, Zong H, Metabolism 2011 60 4 523 530 10.1016/j.metabol.2010.04.021 20580384
40. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL, Ann Epidemiol 2001 11 8 534 542 10.1016/S1047-2797(01)00246-0 11709272 (Pubitemid 33049887)
41. Risk factors for prostate cancer: An hospital-based case-control study from Mumbai, India. Ganesh B, Saoba SL, Sarade MN, Pinjari SV, Indian J Urol 2011 27 3 345 350 10.4103/0970-1591.85438 22022057
42. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR). Martin RM, Vatten L, Gunnell D, Romundstad P, Cancer Causes Control 2010 21 3 463 472 10.1007/s10552-009-9477-x 19949849
43. Body mass index and incidence of localized and advanced prostate cancer-a dose-response meta-analysis of prospective studies. Discacciati A, Orsini N, Wolk A, Ann Oncol 2012 23 7 1665 1671 10.1093/annonc/mdr603 22228452
44. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 1 10 29 10.3322/caac.20138 22237781
45. Metabolic syndrome in adult cancer survivors: a meta-analysis. Jung HS, Myung SK, Kim BS, Seo HG, Diabetes Res Clin Pract 2012 95 2 275 282 10.1016/j.diabres.2011.08.029 22078073